Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece

Nomikos, N.; Naoum, P.; Athanasakis, Kostas; and Kyriopoulos, I

(2024) Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece. Value in Health, 27 (12, Supplement): EE135. S80 - S80. ISSN 1098-3015

Copy

The aim of this study was to evaluate the cost-effectiveness of introducing filgotinib as a treatment option for patients with moderate to severe Ulcerative Colitis(UC) who are biologic-naïve in Greece compared to adalimumab, golimumab and vedolizumab.

Item Type	Article
Keywords	AAM not requested
Departments	Health Policy
DOI	10.1016/j.jval.2024.10.419
Date Deposited	11 Mar 2025 08:36
URI	https://researchonline.lse.ac.uk/id/eprint/127534

Explore Further

Full text not available from this repository.

Atom

BibTeX

OpenURL ContextObject in Span

OpenURL ContextObject

Dublin Core

MPEG-21 DIDL

Data Cite XML

EndNote

HTML Citation

METS

MODS

RIOXX2 XML

Reference Manager

Refer

ASCII Citation

Export

Downloads